The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

The findings suggest that enfortumab vedotin, especially combined with pembrolizumab, offers promising beneficial outcomes in metastatic urothelial carcinoma treatment,” researchers wrote.

Updated data "reinforce enfortumab vedotin and pembrolizumab as the new standard of care in frontline urothelial cancer,” said Thomas Powles, MD, MBBS.

With the rising adoption of checkpoint inhibitors and combination therapies, BAVENCIO's market growth is driven by expanding indications and strategic partnerships. However, competition from ...

DelveInsight's "BAVENCIO Market Size, Forecast, and Market Insight Report" highlights the details around BAVENCIO, a human ...

With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but ...

DelveInsight's "TEPMETKO Market Size, Forecast, and Market Insight Report" highlights the details around TEPMETKO, a kinase ...

Irish speakers can now receive cognitive assessment via their native language due to the launch of a new Irish-language version of the Addenbrooke’s Cognitive Examination (ACE-III). This widely used ...

Assessing the Influence of Smoking on Inflammatory Markers in Bacillus Calmette Guérin Response Among Bladder Cancer Patients: A Novel Machine-Learning Approach - Beyond the Abstract ...

The addition of brentuximab vedotin to lenalidomide and rituximab improved survival for certain patients with DLBCL. A similar percentage of patients in each arm experienced treatment-emergent ...

Notably, NECTIN4 is the target of enfortumab vedotin, an FDA-approved drug for bladder cancer. These discoveries provide new potential drug targets and could lead to improved therapies for cancers ...

Each study, planned to begin in the middle of this year, intends to evaluate ivonescimab plus one of Pfizer’s vedotin ADCs in ... cancer therapy Keytruda (pembrolizumab) in the first-line ...